Show simple item record

Hepatic arterial chemotherapy for primary and metastatic liver cancers

dc.contributor.authorEnsminger, William D.en_US
dc.date.accessioned2006-09-11T18:22:38Z
dc.date.available2006-09-11T18:22:38Z
dc.date.issued1989-01en_US
dc.identifier.citationEnsminger, William; (1989). "Hepatic arterial chemotherapy for primary and metastatic liver cancers." Cancer Chemotherapy and Pharmacology 23(1): S68-S73. <http://hdl.handle.net/2027.42/46919>en_US
dc.identifier.issn0344-5704en_US
dc.identifier.issn1432-0843en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46919
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2647314&dopt=citationen_US
dc.description.abstractHepatic arterial chemotherapy represents a means of selectively exposing hepatic tumor to cytotoxic agents. Although 5-fluoro-2′-deoxyuridine has been shown to generate a higher response rate in the treatment of colorectal liver metastases than that achieved by intravenous infusion, responses are largely incomplete and rarely of long duration. This review describes the rationale for the use of the thymidine analogs 5-bromo-2′-deoxyuridine and 5-iodo-2′-deoxyuridine in hepatic arterial infusions and indicates how combination therapy adding radiotherapy, specifically with hepatic arterially administered yttrium-90 microspheres, might generate a new, more efficient and effective therapeutic approach.en_US
dc.format.extent674166 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherCancer Researchen_US
dc.subject.otherOncologyen_US
dc.titleHepatic arterial chemotherapy for primary and metastatic liver cancersen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUpjohn Center for Clinical Pharmacology, Department of Medicine, University of Michigan Medical School, 48109, Ann Arbor, Michigan, USA; Department of Pharmacology, University of Michigan Medical School, 48109, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2647314en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46919/1/280_2004_Article_BF00647244.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00647244en_US
dc.identifier.sourceCancer Chemotherapy and Pharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.